🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies

RecruitingPhase 1, Phase 2Ages any - anyAllAce Cells Lab Limited
NCT06787482 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Summary of the Study This clinical trial evaluates a novel peptide-based therapy for treating retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR). The therapy consists of peptides derived from fetal tissues, mesenchymal stem cells (MSCs), and bioactive growth factors, administered sublingually for systemic absorption. Study Objectives: Primary Objectives: Assess safety and tolerability, and evaluate the therapy's effects on retinal function and structure. Secondary Objectives: Explore improvements in visual acuity, retinal thickness, vascular health, and disease biomarkers. Study Design: Type: Open-label, single-arm interventional study. Duration: 12 months. Participants: 150 adults, divided into three cohorts: Retinal dystrophies. AMD (dry and wet forms). DR (moderate NPDR and PDR). Intervention: A sublingual solution containing peptides a

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * • Adults aged 18-65 years with a confirmed genetic or clinical diagnosis of RP. * Visual acuity of ≥1/60 in at least one eye. * Stable ocular and systemic condition over the past six months. * Ability to provide written informed consent Exclusion Criteria: * • Significant ocular comorbidities (e.g., advanced glaucoma, diabetic retinopathy). * Recent ocular surgery (within six months) or current use of investigational drugs. * Systemic conditions affecting study outcomes (e.g., uncontrolled diabetes, autoimmune diseases). * Pregnancy or lactation.
💊

What it tests

  • ACE Retino
📍

Where

2 sites
Dr. Seif Clinic
Cairo, Egypt
British Center for Regeerative medicne (Cairo)
Giza, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy